Lexeo Therapeutics, Inc.
No enriched coverage for $LXEO in the last 7 days.
Lexeo Therapeutics, Inc. (LXEO) reported beneficial ownership disclosures by OrbiMed entities. OrbiMed Advisors LLC holds 3,203,050 shares, about 4.1% of the class, and OrbiMed Capital LLC holds 744,800 shares, about 1.0%. Combined, they report 5.0% ownership with shared voting and dispositive control via a management committee.
Lexeo Therapeutics (LXEO) disclosed in a Schedule 13G/A (Amendment No. 3) that Paradigm BioCapital-related entities and Senai Asefaw, M.D. hold beneficial ownership of its common stock. Paradigm BioCapital Advisors LP, GP LLC and Asefaw report 4,175,382 shares, 5.3% of the class, and Paradigm BioCapital International Fund Ltd. reports 3,662,102 shares, 4.7%, based on 78,521,634 shares outstanding as of May 7, 2026.
Lexeo Therapeutics (LXEO) reported Q2 2026 results and updates. It initiated the SUNRISE-FA 2 pivotal trial for LX2006 in June 2026, with first site activated and first patient enrolled. FDA granted RMAT designation for LX2020. Q2 R&D was $19.0M, net loss $25.9M ($0.30/share). Cash was $234.2M. Topline LX2006 data expected 2H 2027.
Recent LXEO coverage spans technology, financial news and regulation.
In the last 30 days, LXEO insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($43K). The most active reporter was Otero Jose Manuel, Chief Operating Officer, with 1 filing.
This is a new ownership disclosure that can affect perceived control, liquidity, and potential future activism or financing narratives, but it is not an operational catalyst.
This is a beneficial-ownership disclosure that can matter for control perception and potential activism risk, but it does not announce a new operational catalyst.
Trial initiation and RMAT designation updates improve near-term clinical/regulatory visibility, but the next major inflection is 2H27 topline.
Near-term catalyst is execution on SUNRISE-FA 2 enrollment and FDA interaction under accelerated approval; RMAT supports LX2020 development optionality.
New clinical execution milestones plus RMAT designation and a stated cash runway into 2028 can re-rate near-term probability of regulatory progress.
alphai scores every news story that mentions LXEO with an AI model for sentiment and relevance, and aggregates insider trades from Lexeo Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lexeo Therapeutics, Inc. (LXEO) reported beneficial ownership disclosures by OrbiMed entities. OrbiMed Advisors LLC holds 3,203,050 shares, about 4.1% of the class, and OrbiMed Capital LLC holds 744,800 shares, about 1.0%. Combined, they report 5.0% ownership with shared voting and dispositive control via a management committee.
2 min readLexeo Therapeutics (LXEO) disclosed in a Schedule 13G/A (Amendment No. 3) that Paradigm BioCapital-related entities and Senai Asefaw, M.D. hold beneficial ownership of its common stock. Paradigm BioCapital Advisors LP, GP LLC and Asefaw report 4,175,382 shares, 5.3% of the class, and Paradigm BioCapital International Fund Ltd. reports 3,662,102 shares, 4.7%, based on 78,521,634 shares outstanding as of May 7, 2026.
2 min readLexeo Therapeutics (LXEO) reported Q2 2026 results and updates. It initiated the SUNRISE-FA 2 pivotal trial for LX2006 in June 2026, with first site activated and first patient enrolled. FDA granted RMAT designation for LX2020. Q2 R&D was $19.0M, net loss $25.9M ($0.30/share). Cash was $234.2M. Topline LX2006 data expected 2H 2027.
5 min readLexeo Therapeutics (Nasdaq: LXEO) reported Q2 2026 results and updates. It finalized SUNRISE-FA 2 protocol and SAP for LX2006, with first patient enrolled in June and site activation ongoing. CLARITY-FA enrollment continues. FDA granted RMAT for LX2020. Cash and investments were $234.2M, funding operations into 2028. R&D was $19.0M and net loss $25.9M ($0.30/share).
4 min readLexeo Therapeutics, Inc. (LXEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lxeo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data
5 min readLexeo Therapeutics (Nasdaq: LXEO) said the FDA granted RMAT designation to its AAV-based gene therapy LX2020 for PKP2-associated arrhythmogenic cardiomyopathy, based on interim data from the HEROIC-PKP2 Phase I/II trial. Lexeo also noted Orphan Drug and Fast Track status. RMAT may support accelerated approval, priority review, and rolling review.
4 min readLexeo Therapeutics (Nasdaq: LXEO) said the FDA granted RMAT designation to its investigational AAV-based gene therapy LX2020 for PKP2-associated arrhythmogenic cardiomyopathy. The decision was based on interim data from the ongoing HEROIC-PKP2 Phase I/II trial. Lexeo also noted LX2020 received Orphan Drug and Fast Track designations.
3 min readLexeo Therapeutics (NASDAQ:LXEO) said it finalized the critical trial protocol and statistical analysis plan for SUNRISE-FA 2, supporting a Biologics License Application to the U.S. FDA for gene therapy candidate LX2006 under the 2028 approval pathway. JPMorgan cut its target to $9 from $12 and kept an Overweight rating.
4 min readTownsend Richard Nolan (Chief Executive Officer) sold 25,947 shares of Lexeo Therapeutics, Inc. (LXEO) at $4.48 ($0.12M total) on 2026-07-01.
2 min readLexeo Therapeutics, Inc. (LXEO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001907108 0001907108 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25,
2 min read